Longitudinal study of antibodies against thyroid in patients undergoing interferon-α therapy for HCV chronic hepatitis

Carlo Carella, Giovanni Amato, Bernadette Biondi, Mario Rotondi, Filomena Morisco, Concetta Tuccillo, Nicola Chiuchiolo, Giuseppe Signoriello, Nicola Caporaso, Gaetano Lombardi

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Seventy-five patients (50 M, 25 F), affected by chronic hepatitis caused by hepatitis C virus (HCV), without clinically overt thyroid disease, underwent r-interferon (IFN)-α-2a treatment (3–6 MU, 3 times/week) for 12 months. They were tested for thyroid function and for thyroid autoantibodies before (A), 6 (B) and 12 (C) months after the beginning of treatment and after 6 (D) months off therapy. Antithyroglobulin antibodies (Tg-Ab) and TSH were measured by IRMA, antiperoxidase antibodies (TPO-Ab), free T3 (FT3) and free T4 (FT4) by RIA, thyrotropin receptor antibodies (TR-Ab) by RRA. None of the patients showed TR-Ab positivity throughout the study. The number of the patients with one or both antithyroid antibodies progressively increased during treatment (A 10.7%; B 26.7%; C 45.3%) and decreased when off therapy (D 22.7%) with none of them positive for Tg-Ab alone (TPO-Ab 6.7%; Tg-Ab + TPO-Ab 16%). Tg-Ab increased during rIFN (median: A 29.0; B 35.0; C 73.0 U/ml) but decreased when off therapy (D 29.0 U/ml). Instead, TPO-Ab significantly increased throughout the study (A 1.0; B 3.0; C 6.0; D 7.0 U/ml). However, some patients showed for the first time an appearance of antibodies when off therapy. Five patients showed both antibodies and thyroid dysfunction: 2 at B, 2 at C, and 1 at D. Only 1 developed mild transient hyperthyroidism while the other 4 developed hypothyroidism, persistent however only in 1 case. Our study confirms that rIFN-α-2a frequently induces thyroid autoimmunity. TPO-Ab seems more useful than Tg-Ab in monitoring the immunological response. Thyroid dysfunction (especially hypothyroidism and in females), always accompanied with the appearance of thyroid autoantibodies, is often transitory in spite of not discontinued treatment. The pretreatment positivity for Tg-Ab was not associated with the subsequent development of thyroid dysfunction, therefore it cannot be considered a risk factor in IFN-α therapy. Finally, the appearance in some cases of TPO-Ab after stopping treatment suggests that the thyroid surveillance in these patients should be prolonged.

Original languageEnglish
Pages (from-to)110-114
Number of pages5
JournalHormone Research in Paediatrics
Volume44
Issue number3
DOIs
Publication statusPublished - 1995

Fingerprint

Chronic Hepatitis
Hepacivirus
Interferons
Longitudinal Studies
Thyroid Gland
Antibodies
Therapeutics
Thyrotropin Receptors
Hypothyroidism
Autoantibodies
Immunologic Monitoring
Thyroid Diseases
Hyperthyroidism
Autoimmunity

Keywords

  • Autoimmunity
  • Hepatitis
  • Interferon
  • Thyroid

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health

Cite this

Longitudinal study of antibodies against thyroid in patients undergoing interferon-α therapy for HCV chronic hepatitis. / Carella, Carlo; Amato, Giovanni; Biondi, Bernadette; Rotondi, Mario; Morisco, Filomena; Tuccillo, Concetta; Chiuchiolo, Nicola; Signoriello, Giuseppe; Caporaso, Nicola; Lombardi, Gaetano.

In: Hormone Research in Paediatrics, Vol. 44, No. 3, 1995, p. 110-114.

Research output: Contribution to journalArticle

Carella, C, Amato, G, Biondi, B, Rotondi, M, Morisco, F, Tuccillo, C, Chiuchiolo, N, Signoriello, G, Caporaso, N & Lombardi, G 1995, 'Longitudinal study of antibodies against thyroid in patients undergoing interferon-α therapy for HCV chronic hepatitis', Hormone Research in Paediatrics, vol. 44, no. 3, pp. 110-114. https://doi.org/10.1159/000184606
Carella, Carlo ; Amato, Giovanni ; Biondi, Bernadette ; Rotondi, Mario ; Morisco, Filomena ; Tuccillo, Concetta ; Chiuchiolo, Nicola ; Signoriello, Giuseppe ; Caporaso, Nicola ; Lombardi, Gaetano. / Longitudinal study of antibodies against thyroid in patients undergoing interferon-α therapy for HCV chronic hepatitis. In: Hormone Research in Paediatrics. 1995 ; Vol. 44, No. 3. pp. 110-114.
@article{1d337be5608d473db78721e3acb5ec30,
title = "Longitudinal study of antibodies against thyroid in patients undergoing interferon-α therapy for HCV chronic hepatitis",
abstract = "Seventy-five patients (50 M, 25 F), affected by chronic hepatitis caused by hepatitis C virus (HCV), without clinically overt thyroid disease, underwent r-interferon (IFN)-α-2a treatment (3–6 MU, 3 times/week) for 12 months. They were tested for thyroid function and for thyroid autoantibodies before (A), 6 (B) and 12 (C) months after the beginning of treatment and after 6 (D) months off therapy. Antithyroglobulin antibodies (Tg-Ab) and TSH were measured by IRMA, antiperoxidase antibodies (TPO-Ab), free T3 (FT3) and free T4 (FT4) by RIA, thyrotropin receptor antibodies (TR-Ab) by RRA. None of the patients showed TR-Ab positivity throughout the study. The number of the patients with one or both antithyroid antibodies progressively increased during treatment (A 10.7{\%}; B 26.7{\%}; C 45.3{\%}) and decreased when off therapy (D 22.7{\%}) with none of them positive for Tg-Ab alone (TPO-Ab 6.7{\%}; Tg-Ab + TPO-Ab 16{\%}). Tg-Ab increased during rIFN (median: A 29.0; B 35.0; C 73.0 U/ml) but decreased when off therapy (D 29.0 U/ml). Instead, TPO-Ab significantly increased throughout the study (A 1.0; B 3.0; C 6.0; D 7.0 U/ml). However, some patients showed for the first time an appearance of antibodies when off therapy. Five patients showed both antibodies and thyroid dysfunction: 2 at B, 2 at C, and 1 at D. Only 1 developed mild transient hyperthyroidism while the other 4 developed hypothyroidism, persistent however only in 1 case. Our study confirms that rIFN-α-2a frequently induces thyroid autoimmunity. TPO-Ab seems more useful than Tg-Ab in monitoring the immunological response. Thyroid dysfunction (especially hypothyroidism and in females), always accompanied with the appearance of thyroid autoantibodies, is often transitory in spite of not discontinued treatment. The pretreatment positivity for Tg-Ab was not associated with the subsequent development of thyroid dysfunction, therefore it cannot be considered a risk factor in IFN-α therapy. Finally, the appearance in some cases of TPO-Ab after stopping treatment suggests that the thyroid surveillance in these patients should be prolonged.",
keywords = "Autoimmunity, Hepatitis, Interferon, Thyroid",
author = "Carlo Carella and Giovanni Amato and Bernadette Biondi and Mario Rotondi and Filomena Morisco and Concetta Tuccillo and Nicola Chiuchiolo and Giuseppe Signoriello and Nicola Caporaso and Gaetano Lombardi",
year = "1995",
doi = "10.1159/000184606",
language = "English",
volume = "44",
pages = "110--114",
journal = "Hormone Research in Paediatrics",
issn = "1663-2818",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Longitudinal study of antibodies against thyroid in patients undergoing interferon-α therapy for HCV chronic hepatitis

AU - Carella, Carlo

AU - Amato, Giovanni

AU - Biondi, Bernadette

AU - Rotondi, Mario

AU - Morisco, Filomena

AU - Tuccillo, Concetta

AU - Chiuchiolo, Nicola

AU - Signoriello, Giuseppe

AU - Caporaso, Nicola

AU - Lombardi, Gaetano

PY - 1995

Y1 - 1995

N2 - Seventy-five patients (50 M, 25 F), affected by chronic hepatitis caused by hepatitis C virus (HCV), without clinically overt thyroid disease, underwent r-interferon (IFN)-α-2a treatment (3–6 MU, 3 times/week) for 12 months. They were tested for thyroid function and for thyroid autoantibodies before (A), 6 (B) and 12 (C) months after the beginning of treatment and after 6 (D) months off therapy. Antithyroglobulin antibodies (Tg-Ab) and TSH were measured by IRMA, antiperoxidase antibodies (TPO-Ab), free T3 (FT3) and free T4 (FT4) by RIA, thyrotropin receptor antibodies (TR-Ab) by RRA. None of the patients showed TR-Ab positivity throughout the study. The number of the patients with one or both antithyroid antibodies progressively increased during treatment (A 10.7%; B 26.7%; C 45.3%) and decreased when off therapy (D 22.7%) with none of them positive for Tg-Ab alone (TPO-Ab 6.7%; Tg-Ab + TPO-Ab 16%). Tg-Ab increased during rIFN (median: A 29.0; B 35.0; C 73.0 U/ml) but decreased when off therapy (D 29.0 U/ml). Instead, TPO-Ab significantly increased throughout the study (A 1.0; B 3.0; C 6.0; D 7.0 U/ml). However, some patients showed for the first time an appearance of antibodies when off therapy. Five patients showed both antibodies and thyroid dysfunction: 2 at B, 2 at C, and 1 at D. Only 1 developed mild transient hyperthyroidism while the other 4 developed hypothyroidism, persistent however only in 1 case. Our study confirms that rIFN-α-2a frequently induces thyroid autoimmunity. TPO-Ab seems more useful than Tg-Ab in monitoring the immunological response. Thyroid dysfunction (especially hypothyroidism and in females), always accompanied with the appearance of thyroid autoantibodies, is often transitory in spite of not discontinued treatment. The pretreatment positivity for Tg-Ab was not associated with the subsequent development of thyroid dysfunction, therefore it cannot be considered a risk factor in IFN-α therapy. Finally, the appearance in some cases of TPO-Ab after stopping treatment suggests that the thyroid surveillance in these patients should be prolonged.

AB - Seventy-five patients (50 M, 25 F), affected by chronic hepatitis caused by hepatitis C virus (HCV), without clinically overt thyroid disease, underwent r-interferon (IFN)-α-2a treatment (3–6 MU, 3 times/week) for 12 months. They were tested for thyroid function and for thyroid autoantibodies before (A), 6 (B) and 12 (C) months after the beginning of treatment and after 6 (D) months off therapy. Antithyroglobulin antibodies (Tg-Ab) and TSH were measured by IRMA, antiperoxidase antibodies (TPO-Ab), free T3 (FT3) and free T4 (FT4) by RIA, thyrotropin receptor antibodies (TR-Ab) by RRA. None of the patients showed TR-Ab positivity throughout the study. The number of the patients with one or both antithyroid antibodies progressively increased during treatment (A 10.7%; B 26.7%; C 45.3%) and decreased when off therapy (D 22.7%) with none of them positive for Tg-Ab alone (TPO-Ab 6.7%; Tg-Ab + TPO-Ab 16%). Tg-Ab increased during rIFN (median: A 29.0; B 35.0; C 73.0 U/ml) but decreased when off therapy (D 29.0 U/ml). Instead, TPO-Ab significantly increased throughout the study (A 1.0; B 3.0; C 6.0; D 7.0 U/ml). However, some patients showed for the first time an appearance of antibodies when off therapy. Five patients showed both antibodies and thyroid dysfunction: 2 at B, 2 at C, and 1 at D. Only 1 developed mild transient hyperthyroidism while the other 4 developed hypothyroidism, persistent however only in 1 case. Our study confirms that rIFN-α-2a frequently induces thyroid autoimmunity. TPO-Ab seems more useful than Tg-Ab in monitoring the immunological response. Thyroid dysfunction (especially hypothyroidism and in females), always accompanied with the appearance of thyroid autoantibodies, is often transitory in spite of not discontinued treatment. The pretreatment positivity for Tg-Ab was not associated with the subsequent development of thyroid dysfunction, therefore it cannot be considered a risk factor in IFN-α therapy. Finally, the appearance in some cases of TPO-Ab after stopping treatment suggests that the thyroid surveillance in these patients should be prolonged.

KW - Autoimmunity

KW - Hepatitis

KW - Interferon

KW - Thyroid

UR - http://www.scopus.com/inward/record.url?scp=0029080477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029080477&partnerID=8YFLogxK

U2 - 10.1159/000184606

DO - 10.1159/000184606

M3 - Article

C2 - 7590640

AN - SCOPUS:0029080477

VL - 44

SP - 110

EP - 114

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

SN - 1663-2818

IS - 3

ER -